The development of the anti-CD38 antibody Daratumumab has redefined the treatment landscape in multiple myeloma (MM), showing impressive anti-tumoral activity in one of the most insidious hematological malignancies [1,2,3,4,5]. Here, CD38 is linked to plasma cell myeloma.